Cargando…
Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status
Metastatic breast cancer (MBC) patient outcomes may vary according to distinct health care payers and different countries. We compared 291 Alberta (AB), Canada and 9429 US patients < 65 with de novo MBC diagnosed from 2010 through 2014. Data were extracted from the provincial Breast Data Mart and...
Autores principales: | Savard, Marie-France, Kornaga, Elizabeth N., Kahn, Adriana Matutino, Lupichuk, Sasha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774867/ https://www.ncbi.nlm.nih.gov/pubmed/35049708 http://dx.doi.org/10.3390/curroncol29010034 |
Ejemplares similares
-
Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study
por: Batra, Atul, et al.
Publicado: (2020) -
Four Cycles of Docetaxel-Cyclophosphamide versus Anthracycline-Taxane as Adjuvant Chemotherapy for HER2-Negative, Axillary Lymph Node Negative Breast Cancer: A Real-World Comparison of Alberta Patients Treated 2008–2012
por: Hannouf, Malek, et al.
Publicado: (2021) -
Real-World Use of Androgen-Deprivation Therapy: Intensification Among
Older Canadian Men With de Novo Metastatic Prostate Cancer
por: Wallis, Christopher J D, et al.
Publicado: (2021) -
A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab
por: Yang, Charlie, et al.
Publicado: (2022) -
Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2–Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes
por: Lupichuk, Sasha, et al.
Publicado: (2019)